Carcinoma, Non-Small-Cell Lung Clinical Trial
Official title:
Evaluation in Real World of Molecular Testing and Treatment Patterns for EGFR Mutations in Patients With Advanced or Metastatic NSCLC at Front-line and Progression
Evaluate molecular testing and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs. This study is non-indication seeking (NIS), descriptive in nature and does not attempt to test any specific a priori hypotheses.
Objectives and Hypotheses : The objectives of this study are to evaluate molecular testing
and treatment patterns for EGFR mutation in two different cohorts of stage IV NSCLC, at
diagnosis (treatment naïve) and at the moment of progression to EGFR-TKIs. This study is
non-indication seeking (NIS), descriptive in nature and does not attempt to test any specific
a priori hypotheses. The following study objectives will be assessed:
Primary Objectives
- To estimate parameters associated with molecular testing patterns at diagnosis of
advance disease and progression to EGFR TKIs
- To estimate parameters associated with treatment patterns at frontline and at
progression to a EGFR TKI therpay
Secondary Objectives
- To estimate the rate of central nervous system (CNS) metastases at diagnosis and after
disease progression in EGFR+ NSCLC patients
- To estimate parameters associated with biopsy related complications
Study Design This will be an observational retrospective study of patients with Stage IV
NSCLC in two different cohorts from participating sites in Uruguay, Argentina, Costa Rica,
Colombia, Chile, Peru, and Republica Dominicana. Cohort 1: newly diagnosed Stage IV NSCL who
are treatment naive Cohort 2: stage IV NSCLC EGFRm progressed after first or second
generation EGFR-TKI
Data of patients meeting the study inclusion/exclusion criteria will be collected from
diagnosis of Satge IV (cohort 1) or diagnosis of progression after first or second generation
EGFR-TKI (cohort 2) until the maximum follow up registered in the medical record.
Data will be collected and entered in the electronic case report form (eCRF). All data will
be collected using patient medical records. The investigator will be responsible for ensuring
that all the required data is collected and entered into the eCRF. The site will collect the
data that will be uploaded according to the data entry procedures.
Study Population Cohort
1: all registered cases of stage IV NSCLC patients, treatment naïve, diagnosed in the
participant institution during one year (from Jan 1st 2017 to Dec 31st 2017). Cohort 2: all
EGFR positive patients progressed to an EFGR-TKI in the same period of time (from Jan 1st
2017 to Dec 31st 2017)
In the case one patient meets eligibility criteria for both cohorts, this patient will be
included only in the EFGR-TKI progressed cohort.
Exposures There are no specific drug exposures or interventions being evaluated, as cohort
eligibility is not exposure-based, but rather disease-based.
Study Measures
- Patient demographic and clinical characteristics
- Molecular testing rates at Stage IV and at progression to EGFR TKI
- Molecular testing EGFR mutation results (common/uncommon mutations at advanced
diagnosis, and T790M at progression)
- Treatment patterns at frontline and progression to EGFR TKIs
- Biopsy-related complications
- Percentage of patinets presenting with CNS metastasis at diagnosis of stage IV and at
progression to EGFR TKIsCNS
Sample:
All patients diagnosed with Stage IV NSCLC at diagnosis and at progression to an EGFR-TKI;
from January 1st , 2017 to December 31st, 2017 in selected centers of Uruguay, Argentina,
Chile, Colombia
Statistical Analysis No formal hypothesis testing is specified. Study measures including
patient demographics and clinical characteristics, molecular testing rates and patterns,
treatment patterns. Continuous study measures (e.g., age) will be reported descriptively with
mean, standard deviation, median, minimum and maximum. Frequencies and percentages will be
used to document categorical measures of interest (e.g., number and proportion of patients
with a molecular test, number and proportion of patients with a EGFR mutation) and will
include 95% CIs for key outcome variables.
Study Duration Estimated date of First Patient Data In: Q3 2018
Estimated date of Data Base Lock: Q1 2019
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04879849 -
A Study of TAK-676 With Pembrolizumab After Radiation Therapy to Treat a Number of Cancers
|
Phase 1 | |
Completed |
NCT04426825 -
A Study of Atezolizumab in Combination With Bevacizumab in Patients With EGFR Mutation Positive Stage IIIB-IV Non-Squamous Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT03166631 -
A Trial to Find the Safe Dose for BI 891065 Alone and in Combination With BI 754091 in Patients With Incurable Tumours or Tumours That Have Spread
|
Phase 1 | |
Completed |
NCT02864394 -
Study of Pembrolizumab Versus Docetaxel in Participants Previously Treated for Non-Small Cell Lung Cancer (MK-3475-033/KEYNOTE-033)
|
Phase 3 | |
Completed |
NCT02810457 -
Evaluation of FKB238 and Avastin in Patients With Advanced/Recurrent Non-squamous Non-small Cell Lung Cancer
|
Phase 3 | |
Recruiting |
NCT04592523 -
A Study of Usage of Brigatinib in the Treatment of Adult Participants for Approved Indications In South Korea
|
||
Recruiting |
NCT04838548 -
A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer
|
Phase 2 | |
Recruiting |
NCT04077463 -
A Study of Lazertinib as Monotherapy or in Combination With Amivantamab in Participants With Advanced Non-small Cell Lung Cancer
|
Phase 1 | |
Recruiting |
NCT04603807 -
A Study to Compare the Efficacy and Safety of Entrectinib and Crizotinib in Participants With Advanced or Metastatic ROS1 Non-small Cell Lung Cancer (NSCLC) With and Without Central Nervous System (CNS) Metastases
|
Phase 3 | |
Recruiting |
NCT05167604 -
Clinical Value of MRD Monitoring for Adjuvant Therapy in Postoperative NSCLC
|
||
Completed |
NCT04948411 -
Durvalumab as Maintenance in Patients Who Received Chemoradiotherapy for Unresectable Stage III NSCLC: Real World Data From an Expanded Access Program in Brazil
|
||
Active, not recruiting |
NCT04487080 -
A Study of Amivantamab and Lazertinib Combination Therapy Versus Osimertinib in Locally Advanced or Metastatic Non-Small Cell Lung Cancer
|
Phase 3 | |
Not yet recruiting |
NCT04255836 -
Durvalumab Combined With Chemotherapy and Stereotactic Body Radiotherapy (SBRT) in Patients With Oligometastatic Non-small Cell Lung Cancer (NSCLC)
|
Phase 2 | |
Completed |
NCT01953913 -
Afatinib (BIBW 2992) in Advanced Non-Small Cell Lung Cancer Patients With EGFR Mutation
|
Phase 3 | |
Recruiting |
NCT05715229 -
Immune Profile Selection By Fraction of ctDNA in Patients With Advanced NSCLC Treated With Immunotherapy
|
Phase 2 | |
Recruiting |
NCT04931654 -
A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer
|
Phase 1/Phase 2 | |
Suspended |
NCT05421936 -
Osimertinib for NSCLC With Uncommon EGFR Mutations
|
||
Completed |
NCT02847377 -
A Positron Emission Tomography (PET) Imaging Agent [18F]-ODS2004436 as a Marker of EGFR Mutation in Subjects With NSCLC
|
N/A | |
Completed |
NCT04427072 -
Study of Capmatinib Efficacy in Comparison With Docetaxel in Previously Treated Participants With Non-small Cell Lung Cancer Harboring MET Exon 14 Skipping Mutation
|
Phase 3 | |
Recruiting |
NCT04823377 -
Impact of a Process Optimizing the Decision to Continue or Stop Cancer Treatments in Patients With Advanced Non-small Cell Lung Cancer.
|
N/A |